




PHARMACEUTICAL 2021

Rezolute Inc.
Rank 335 of 402





PHARMACEUTICAL 2021

Rezolute Inc.
Rank 335 of 402

The relative strengths and weaknesses of Rezolute Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Rezolute Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 20% points. The greatest weakness of Rezolute Inc. is the variable Net Income, reducing the Economic Capital Ratio by 179% points.

The company's Economic Capital Ratio, given in the ranking table, is -105%, being 153% points below the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	10,518
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,226
Liabilities, Non-Current	165
Other Assets	414
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	209
Other Net Income	188
Other Revenues	0
Property and Equipment	33
Research and Development	14,450
Selling, General and Administrative Expense	6,071

Output Variable	Value in 1000 USD
Assets	10,965
Liabilities	3,600
Expenses	20,521
Revenues	0
Stockholders Equity	7,365
Net Income	-20,333
Comprehensive Net Income	-20,333
Economic Capital Ratio	-105%